Statement of Changes in Stockholders' Equity - USD ($)	Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Accumulated Deficit [Member]	Total
Balance at Jun. 30, 2019	$ 256	$ 3,845	$ 102,712,845	$ (92,116,586)	$ 10,600,360
Balance (in shares) at Jun. 30, 2019	255,714	3,844,921
Series A Preferred Stock issued for employee stock compensation			51,398		51,398
Series A Preferred Stock issued for employee stock compensation (in shares)	387
Common stock issued for consulting and legal services rendered		$ 6	26,994		27,000
Common stock issued for consulting and legal services rendered (in shares)		6,201
Warrants issued to Scientific Advisory Board			908		908
Common shares issued for Directors fees		$ 3	11,247		11,250
Common shares issued for Directors fees (in shares)		2,553
Net loss				(1,561,133)	(1,561,133)
Balance at Sep. 30, 2019	$ 256	$ 3,854	102,803,392	(93,677,719)	9,129,783
Balance (in shares) at Sep. 30, 2019	256,101	3,853,675
Balance at Jun. 30, 2019	$ 256	$ 3,845	102,712,845	(92,116,586)	10,600,360
Balance (in shares) at Jun. 30, 2019	255,714	3,844,921
Net loss					(11,571,963)
Balance at Mar. 31, 2020	$ 368	$ 7,673	117,995,269	(103,688,549)	14,314,761
Balance (in shares) at Mar. 31, 2020	368,215	7,673,357
Balance at Sep. 30, 2019	$ 256	$ 3,854	102,803,392	(93,677,719)	9,129,783
Balance (in shares) at Sep. 30, 2019	256,101	3,853,675
Series A Preferred Stock issued for employee stock compensation			49,394		49,394
Series A Preferred Stock issued for employee stock compensation (in shares)	387
Series A Preferred Stock issued for accounts payable-related party	$ 100		392,569		392,669
Series A Preferred Stock issued for accounts payable-related party (in Shares)	100,000
Series A Preferred Stock issued for loan origination fee	$ 10		39,291		39,301
Series A Preferred Stock issued for loan origination fee (in shares)	10,000
Common stock issued for consulting and legal services rendered		$ 12	26,988		27,000
Common stock issued for consulting and legal services rendered (in shares)		11,932
Warrants issued to Scientific Advisory Board			533		533
Common shares issued for Directors fees		$ 5	11,245		11,250
Common shares issued for Directors fees (in shares)		4,965
Net loss				(1,927,526)	(1,927,526)
Balance at Dec. 31, 2019	$ 366	$ 3,871	103,323,412	(95,605,245)	7,722,404
Balance (in shares) at Dec. 31, 2019	366,488	3,870,572
Series A Preferred Stock issued for employee stock compensation	$ 2		73,465		73,467
Series A Preferred Stock issued for employee stock compensation (in shares)	1,727
Common stock issued for accounts payable		$ 9	51,991		52,000
Common stock issued for accounts payable (In shares)		8,467
Common stock issued in exchange for warrants		$ 677	5,721,866		5,722,543
Common stock issued in exchange for warrants (In shares)		677,224
Common stock issued upon cashless exercise of warrants		$ 180	1,153,701		1,153,881
Common stock issued upon cashless exercise of warrants (In shares)		180,087
Net proceeds from issuance of common stock in connection with equity financings		$ 2,875	7,454,700		7,457,575
Net proceeds from issuance of common stock in connection with equity financings (in shares)		2,875,000
Common stock issued for consulting and legal services rendered		$ 56	173,194		173,250
Common stock issued for consulting and legal services rendered (in shares)		56,854
Warrants issued to Scientific Advisory Board			2,444		2,444
Common stock issued for employee compensation		$ 4	29,247		29,251
Common stock issued for employee compensation (in shares)		3,572
Common shares issued for Directors fees		$ 1	11,249		11,250
Common shares issued for Directors fees (in shares)		1,581
Net loss				(8,083,304)	(8,083,304)
Balance at Mar. 31, 2020	$ 368	$ 7,673	117,995,269	(103,688,549)	14,314,761
Balance (in shares) at Mar. 31, 2020	368,215	7,673,357
Balance at Jun. 30, 2020	$ 369	$ 9,083	127,311,634	(105,563,124)	21,757,962
Balance (in shares) at Jun. 30, 2020	368,602	9,083,414
Series A Preferred Stock issued for employee stock compensation	$ 0	$ 0	53,098	0	53,098
Series A Preferred Stock issued for employee stock compensation (in shares)	387	0
Net proceeds from issuance of common stock in connection with equity financings		$ 1,576	10,440,640		10,442,216
Net proceeds from issuance of common stock in connection with equity financings (in shares)		1,575,342
Common stock issued for consulting and legal services rendered		$ 5	26,995		27,000
Common stock issued for consulting and legal services rendered (in shares)		5,135
Warrants issued to Scientific Advisory Board			1,986		1,986
Common shares issued for Directors fees		$ 2	11,248		11,250
Common shares issued for Directors fees (in shares)		2,040
Net loss				(2,311,233)	(2,311,233)
Balance at Sep. 30, 2020	$ 369	$ 10,666	137,845,601	(107,874,357)	29,982,279
Balance (in shares) at Sep. 30, 2020	368,989	10,665,931
Balance at Jun. 30, 2020	$ 369	$ 9,083	127,311,634	(105,563,124)	21,757,962
Balance (in shares) at Jun. 30, 2020	368,602	9,083,414
Net loss					(6,749,317)
Balance at Mar. 31, 2021	$ 371	$ 11,505	144,190,346	(112,312,441)	31,889,781
Balance (in shares) at Mar. 31, 2021	371,103	11,504,693
Balance at Sep. 30, 2020	$ 369	$ 10,666	137,845,601	(107,874,357)	29,982,279
Balance (in shares) at Sep. 30, 2020	368,989	10,665,931
Series A Preferred Stock issued for employee stock compensation			50,602		50,602
Series A Preferred Stock issued for employee stock compensation (in shares)	387
Common stock issued for consulting and legal services rendered		$ 7	26,993		27,000
Common stock issued for consulting and legal services rendered (in shares)		7,411
Warrants issued to Scientific Advisory Board			1,215		1,215
Common shares issued for Directors fees		$ 4	14,996		15,000
Common shares issued for Directors fees (in shares)		4,106
Net loss				(2,330,054)	(2,330,054)
Balance at Dec. 31, 2020	$ 369	$ 10,677	137,939,407	(110,204,411)	27,746,042
Balance (in shares) at Dec. 31, 2020	369,376	10,677,448
Series A Preferred Stock issued for employee stock compensation	$ 2		71,498		71,500
Series A Preferred Stock issued for employee stock compensation (in shares)	1,727
Net proceeds from issuance of common stock in connection with equity financings		$ 815	6,120,666		6,121,481
Net proceeds from issuance of common stock in connection with equity financings (in shares)		814,242
Common stock issued for consulting and legal services rendered		$ 6	26,994		27,000
Common stock issued for consulting and legal services rendered (in shares)		6,131
Warrants issued to Scientific Advisory Board			1,750		1,750
Common stock issued for employee compensation		$ 4	15,034		15,038
Common stock issued for employee compensation (in shares)		3,572
Common shares issued for Directors fees		$ 3	14,997		15,000
Common shares issued for Directors fees (in shares)		3,300
Net loss				(2,108,030)	(2,108,030)
Balance at Mar. 31, 2021	$ 371	$ 11,505	$ 144,190,346	$ (112,312,441)	$ 31,889,781
Balance (in shares) at Mar. 31, 2021	371,103	11,504,693